Foley Hoag’s Government Strategies practice is active in all aspects of policymaking at the federal level. Our lawyers collaborate with our clients and the public sector to achieve mutually beneficial solutions to public policy issues. We pride ourselves on our ability to secure our clients’ strategic goals by combining a deep, substantive knowledge of issues critical to our clients’ businesses and industries with a mastery of federal legislative and regulatory processes. learn more

News more

  • Foley Hoag Wins Dismissal of Suit against Venezuelan Government that Hinged on Energy Minister’s Forged Signature  [Read More]
  • Foley Hoag Represents Ecuador in Suit against Colombia, Seeking to Stop Aerial Coca Spraying That Has Dispersed into Ecuador, Sickening Villagers and Livestock, Damaging Croplands and Poisoning Ecosystems  [Read More]
  • Foley Hoag Selected as one of 2008 Top 100 Law Firms for Diversity  [Read More]
  • Kelly Childress Joins Foley Hoag's Government Strategies Group  [Read More]
  • Bruce Quinn, MD, PhD Joins the Foley Hoag Government Strategies Practice as Health Policy Specialist  [Read More]

Publications more

  • New IRS Annual Information Return Required for Small Tax-Exempt Organizations – Form 990-N (e-Postcard) [Read More]
  • Prescription Drug Pedigree: Proliferation of State Laws Calls for Federal Action [Read More]
  • Crossing the Three Chasms: Complex Molecular Testing and Medicare Regulations [Read More]
  • Health Canada Releases Draft Biosimilar Approval Guidance [Read More]
  • Bipartisan Follow-on-Biologics Legislation Introduced in the House [Read More]

Events more

May 20, 2008 Deciphering the Funding Value-Chain: How Seed Capital Scroungers Become Bankers' Best Friends [Read More] Emerging Enterprise Center at Foley Hoag
Waltham, MA
May 29, 2008 FDA Boot Camp: Basic Training for Products Liability and Patent Lawyers [Read More] Hotel Whitcomb
San Francisco, CA
June 4, 2008 What's New in Selected Fields - Neuroscience and Neurotechnology [Read More] Emerging Enterprise Center at Foley Hoag
Waltham, MA
June 17, 2008 BIO 2008 International Convention [Read More] San Diego Convention Center
San Diego, CA
June 18, 2008 A Case Study of a Biotechnology-Related Action Before the International Trade Commission [Read More] San Diego Convention Center
San Diego, CA

Client Successes more

  • Biomedical Advanced Research and Development Authority (BARDA)
    In a move that created enormous opportunities for early-stage life sciences companies, last year the U.S. Congress revitalized the federal government’s program supporting the development of medical countermeasures critical to protecting the nation against bioterrorism and pandemic threats. The resulting legislation created an agency within the Department of Health and Human Services (HHS), the Biomedical Advanced Research and Development Authority (BARDA). BARDA will inject more than $1 billion into research, development, and procurement of vaccines, antivirals and diagnostics. BARDA enhances coordination between government and emerging companies through support of advanced research and development, the vital phase that occurs in between basic research and commercialization. On behalf of the venture capital firm, Kleiner Perkins Caulfield & Byers, Foley Hoag worked with the HHS, Congressional members, and staff to craft legislation strengthening the nation’s response to pandemic outbreaks and bioterrorism. The key financing aspect of the legislation provides much-needed funding to allow early stage companies to traverse the “valley of death” before product commercialization. The legislation authorizes the Secretary of HHS to expedite contracts and grants, and the Director of BARDA to identify areas of unmet need, spurring further innovation and investment. BARDA institutionalizes the important partnership between the federal government and the life sciences industry, critical to safety, innovation and economic vitality. [Read More]
  • Bringing Law and Science Together
    On behalf of a leading biotechnology company, our Government Strategies lawyers assembled a persuasive legal and scientific case that secured a critical federal policy decision affecting the coding and payment of important therapies for Medicare beneficiaries. [Read More]